Antidote Therapeutics Inc entered the industry of Commercial Biotechnical Research in 2013 and has grown to employ 1 to 4 people, generating an annual revenue of $50.000 to $99.999. The NAICS classifies this business under the code 541711, which describes it as a Commercial Biotechnical Research. For further clarification, the SIC classifies this business under the code 8731 and described it as a Commercial Biotechnical Research. The business provides service to the B2B market.
To acquire more information, please contact Matthew Kalnik by calling (301) 365-5385 during business hours. You can also write to the business’ Single Location at 8202 Wahly Drive, Bethesda, Maryland MD 20817. You can also visit the company’s website at . View this business’ social media profiles on Twitter or on Facebbok .
| Company: | Antidote Therapeutics Inc |
| Representative: | Matthew Kalnik |
| Place of Business: | 8202 Wahly Drive, Bethesda, MD 20817 |
| Contact Number: | (301) 365-5385 |
| Type of Service: | Commercial Biotechnical Research |
| SIC Number: | 8731 |
| NAICS Number: | 541711 |
| Locality: | Single Location |
| Market Type: | B2B (Business to Business) |
| Began: | 2013 |
| Income/Year: | $50.000 to $99.999 |
| Laborers: | 1 to 4 |
| Share This Company: |
Antidote Therapeutics Inc is a company operating from Montgomery, Maryland providing professional Commercial Biotechnical Research and relevant B2B variables. It was founded in 2013 and registered with the SIC code 8731 as Commercial Biotechnical Research, and with the NAICS code 541711 as Commercial Biotechnical Research.
With a current employee count of 1 to 4, Antidote Therapeutics Inc has gone to report making $50.000 to $99.999 per annum on its journey towards growth. This company invites you to contact its representative Matthew Kalnik at (301) 365-5385 for related queries, or to locate its Single Location using the coordinates 38.991498,-77.134879.
The Single Location can also be found at the street address 8202 Wahly Drive in Bethesda, Maryland 20817 and can be engaged online through the company website at , the company Twitter , and Facebook page .